Klaas Financial Asset Advisors’s Biogen BIIB Stock Holding History

Klaas Financial Asset Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$27K	–	44
2022 Q3	$27K	Hold	100	–	–	0.01%	60
2022 Q2	$20K	Hold	100	–	–	0.01%	60
2022 Q1	$21K	Hold	100	–	–	﹤0.01%	60
2021 Q4	$24K	Hold	100	–	–	0.01%	60
2021 Q3	$28K	Hold	100	–	–	0.01%	59
2021 Q2	$35K	Hold	100	–	–	0.01%	56
2021 Q1	$28K	Hold	100	–	–	0.01%	52
2020 Q4	$24K	Buy	+100	New	+$25.8K	0.01%	53

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Klaas Financial Asset Advisors's BIIB Position: Q4 2022 in Review

Klaas Financial Asset Advisors sold out of Biogen (BIIB) in Q4 2022, closing a stake of 100 shares — an estimated $27K sold.

Klaas Financial Asset Advisors first reported a position in BIIB in Q4 2020 and held it in 8 quarters. The position peaked at $35K in Q2 2021. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Klaas Financial Asset Advisors reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Klaas Financial Asset Advisors sold 100 Biogen shares in Q4 2022, an estimated $27K.
Klaas Financial Asset Advisors first reported a position in Biogen in Q4 2020 and held it in 8 quarters.
Klaas Financial Asset Advisors's Biogen position peaked at $35K in Q2 2021.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Klaas Financial Asset Advisors's 13F filing for Q4 2022, filed 23 Jan 2023.